Open Payments Expansion Act
- Bill Number
- S. 2710
- Origin Chamber
- Senate
- Congress
- 119th Congress, Session 1
- Policy Area
- Health
- Status
- Introduced
- Latest Action
- 2025-09-04: Read twice and referred to the Committee on Finance.
- Last Updated
- 2025-09-23T14:37:48Z
AI-Generated Summary
Purpose
The Open Payments Expansion Act aims to increase transparency in the healthcare industry by requiring pharmaceutical and medical device manufacturers to publicly report financial payments or transfers of value made to patient advocacy organizations. This builds on the existing Open Payments program, which tracks industry interactions with healthcare providers, to help prevent undue influence on patient advocacy efforts.
Key Provisions
- Reporting Requirement: Starting March 31, 2027, and on the 90th day of each subsequent calendar year, applicable manufacturers (pharmaceutical and device companies) and applicable group purchasing organizations must submit electronic reports to the Secretary of Health and Human Services (HHS). These reports detail "covered payments" to patient advocacy organizations, including the organization's name and the payment amount.
- Definition of Covered Payments: Includes any direct payment or transfer of value (e.g., money, gifts, or services) and indirect payments (those routed through a third party at the manufacturer's direction or instruction).
- Definition of Patient Advocacy Organization: A tax-exempt nonprofit under Section 501(c)(3) of the Internal Revenue Code that focuses on educating, advocating for, or supporting patients and caregivers with medical conditions diagnosed by licensed professionals, or aiding vulnerable individuals and their families affected by such conditions.
- Public Database Integration: The reported information will be added to the existing Open Payments public database, making it accessible online.
- Administrative Exemption: The law is exempt from the Paperwork Reduction Act (Chapter 35 of Title 44, U.S. Code), which normally requires federal agencies to minimize paperwork burdens on the public.
Significant Changes to Existing Law
- Amends Section 1128G of the Social Security Act (42 U.S.C. 1320a-7h), which established the Open Payments program in 2010 under the Affordable Care Act. Previously, reporting was limited to payments to physicians and teaching hospitals; this expands it to include patient advocacy organizations.
- Updates database access provisions to explicitly include patient advocacy organizations alongside covered recipients (e.g., doctors).
Potential Impacts
- On Government Agencies: HHS will need to update its Open Payments database and reporting systems to handle new data, potentially increasing administrative workload but improving oversight of industry influences.
- On Citizens and Patients: Provides greater public access to information about financial ties between drug/device makers and advocacy groups, empowering patients, caregivers, and the public to evaluate potential biases in advocacy messaging or policy influence.
- On International Relations: Minimal direct impact, though it could indirectly affect U.S.-based multinational pharma companies by standardizing transparency expectations that might influence global practices.
- Broader Effects: May reduce hidden conflicts of interest, promote accountability in patient advocacy, and encourage more ethical funding practices, though it could strain smaller advocacy groups reliant on industry support.
Main Stakeholders Affected
- Pharmaceutical and Device Manufacturers: Primary reporters; face new compliance obligations and potential reputational risks from public disclosures.
- Applicable Group Purchasing Organizations: Entities that buy drugs/devices in bulk for healthcare providers; must also report payments.
- Patient Advocacy Organizations: Nonprofits focused on patient support; will see their funding sources become more visible, which could affect donor relationships and public trust.
- Federal Government (HHS): Oversees implementation, data collection, and public dissemination.
- Patients, Caregivers, and the Public: Benefit from enhanced transparency to make informed decisions about healthcare advocacy and influences.
Notable Legal, Constitutional, or Political Implications
- Legal Implications: Strengthens enforcement of transparency laws without creating new penalties; relies on existing HHS authority for data collection. The exemption from the Paperwork Reduction Act streamlines implementation but could face challenges if seen as bypassing standard regulatory reviews.
- Constitutional Implications: No apparent conflicts with free speech or due process, as it mandates factual disclosures rather than restricting activities. It aligns with First Amendment precedents allowing government-required transparency for public interest (e.g., similar to financial disclosures for lobbyists).
- Political Implications: Bipartisan sponsorship (by Senators Grassley and Hassan) highlights cross-party support for curbing pharma influence. Could spark debates on industry funding of advocacy, potentially leading to further reforms in healthcare lobbying, but might face opposition from manufacturers concerned about competitive harms from disclosures.
This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.
Sponsor
Cosponsors (1)
Sen. Hassan, Margaret Wood [D-NH]
Recent Actions
- 2025-09-04: Read twice and referred to the Committee on Finance.
- 2025-09-04: Introduced in Senate
Bill Versions
- Open Payments Expansion Act — issued 2025-09-04 — PDF (4 pages)